Revvity Dirección

Dirección controles de criterios 3/4

El CEO de Revvity's es Prahlad Singh , nombrado en Jan 2019, tiene una permanencia de 5.25 años. compensación anual total es $9.13M, compuesta por 11.9% salario y 88.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de R$66.41M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 6.5 años, respectivamente.

Información clave

Prahlad Singh

Chief Executive Officer (CEO)

US$9.1m

Compensación total

Porcentaje del salario del CEO	11.9%
Permanencia del CEO	5.4yrs
Participación del CEO	0.1%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Prahlad Singh en comparación con los beneficios de Revvity?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$183m
Dec 31 2023	US$9m	US$1m	US$180m
Oct 01 2023	n/a	n/a	US$213m
Jul 02 2023	n/a	n/a	US$250m
Apr 02 2023	n/a	n/a	US$353m
Jan 01 2023	US$11m	US$1m	US$513m
Oct 02 2022	n/a	n/a	US$599m
Jul 03 2022	n/a	n/a	US$637m
Apr 03 2022	n/a	n/a	US$694m
Jan 02 2022	US$10m	US$1m	US$889m
Oct 03 2021	n/a	n/a	US$1b
Jul 04 2021	n/a	n/a	US$1b
Apr 04 2021	n/a	n/a	US$1b
Jan 03 2021	US$9m	US$900k	US$631m
Oct 04 2020	n/a	n/a	US$412m
Jul 05 2020	n/a	n/a	US$294m
Apr 05 2020	n/a	n/a	US$226m
Dec 29 2019	US$4m	US$645k	US$228m
Sep 29 2019	n/a	n/a	US$235m
Jun 30 2019	n/a	n/a	US$251m
Mar 31 2019	n/a	n/a	US$247m
Dec 30 2018	US$2m	US$517k	US$237m
Sep 30 2018	n/a	n/a	US$128m
Jul 01 2018	n/a	n/a	US$149m
Apr 01 2018	n/a	n/a	US$147m
Dec 31 2017	US$2m	US$464k	US$157m

Compensación vs. Mercado: La compensación total de Prahlad($USD9.13M) está por encima de la media de empresas de tamaño similar en el mercado BR ($USD6.07M).

Compensación vs. Ingresos: La compensación de Prahlad ha sido consistente con los resultados de la empresa en el último año.

CEO

Prahlad Singh (59 yo)

5.4yrs

Permanencia

US$9,130,624

Compensación

Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of Revvity, Inc. (formerly known as PerkinElmer, Inc.) since December 30, 2019. Dr. Singh served as the Chairman of the Supervisory Board at E...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Prahlad Singh	CEO, President & Director	5.4yrs	US$9.13m	0.10% $ 75.7m
Maxwell Krakowiak	Senior VP & CFO	1.8yrs	US$2.75m	0.0026% $ 1.9m
Tajinder Vohra	Senior Vice President of Global Operations	6.4yrs	US$1.76m	0.021% $ 15.5m
Joel Goldberg	Senior VP of Administration	15.9yrs	US$2.64m	0.085% $ 62.2m
Miriame Victor	Senior VP & Chief Commercial Officer	3.4yrs	US$1.70m	0.0072% $ 5.2m
Andrew Okun	VP, Chief Accounting Officer & Treasurer	13.2yrs	sin datos	0.00053% $ 388.6k
Bryan Kipp	Senior Vice President of Technology & Licensing	less than a year	sin datos	sin datos
Madhuri Hegde	Senior VP & Chief Scientific Officer	no data	sin datos	sin datos
Stephen Willoughby	Senior VP of Investor Relations & Head of ESG	no data	sin datos	sin datos
Magali Four	Senior VP & Chief People and Culture Officer	no data	sin datos	sin datos
Robert Friel	Advisor	4.5yrs	US$16.48m	sin datos
Kevin Willoe	Senior VP & GM of Revvity Signals Software	no data	sin datos	sin datos

5.0yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de R1VT34 se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Prahlad Singh	CEO, President & Director	4.8yrs	US$9.13m	0.10% $ 75.7m
Alexis Michas	Independent Non-Executive Chairman	23.4yrs	US$465.08k	0.055% $ 40.0m
Peter Barrett	Independent Director	12.3yrs	US$310.07k	0.018% $ 13.4m
Franklin Witney	Independent Director	7.9yrs	US$295.07k	0.014% $ 10.5m
Samuel Chapin	Independent Director	7.7yrs	US$315.07k	0.014% $ 10.1m
Sophie Vandebroek	Independent Director	less than a year	sin datos	0.0014% $ 1.0m
Pascale Witz	Independent Director	6.7yrs	US$290.07k	0.0084% $ 6.1m
Michel Vounatsos	Independent Director	4.3yrs	US$305.07k	0.0067% $ 4.9m
Michael Klobuchar	Independent Director	less than a year	sin datos	0.0014% $ 1.0m
Michelle McMurry-Heath	Independent Director	1.9yrs	US$290.07k	0.0032% $ 2.4m

5.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de R1VT34 se considera experimentada (6.5 años de antigüedad promedio).

Revvity Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors

PerkinElmer, Inc., Annual General Meeting, Apr 27, 2021

Recent updates

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors

PerkinElmer, Inc. to Report Q2, 2022 Results on Aug 04, 2022

PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Value-Defensive Index

Perkinelmer Introduces Next Generation, Automated Gas Chromatography Platform

PerkinElmer Expands Food Safety Testing Portfolio with AOAC Certified Microbial Count Plates

PerkinElmer, Inc. Launches BioQule NGS System to Automate Library Preparation

PerkinElmer, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022

PerkinElmer, Inc. to Report Q1, 2022 Results on May 03, 2022

PerkinElmer, Inc. Expands in Vivo Instruments Portfolio with Hands-Free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System

PerkinElmer, Inc. Introduces First Ready-To-Use HTRF and AlphaLISA Assay Kits for CHO HCP Impurities Detection and Quantification

Perkinelmer, Inc. Launches ChemDraw V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft Powerpoint Reports

PerkinElmer, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

PerkinElmer, Inc. Declares Quarterly Dividend, Payable on May 13, 2022

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country Channel Partner for Milk and Dairy Testing Solutions

PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance

PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management

PerkinElmer, Inc. Receives U.S. Food and Drug Administration Emergency Use Authorization for PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 Assay

PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins

PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Growth Index

PerkinElmer, Inc. (NYSE:PKI) completed the acquisition of Nexcelom Bioscience LLC from Ampersand Capital Partners.

PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire SIRION Biotech GmbH.

PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire Nexcelom Bioscience LLC for $260 million.

PerkinElmer, Inc. Provides Earnings Guidance for Second Quarter and Full Year 2021

Perkinelmer, Inc. Declares Regular Quarterly Dividend, Payable on August 6, 2021

Perkinelmer, Inc. Provides Revenue Guidance for the First Quarter Ended April 4, 2021

PerkinElmer Launches Industry-First CRM Reagent and Consumable Kit to Streamline Cannabis Pesticide Testing Workflows

PerkinElmer, Inc., Annual General Meeting, Apr 27, 2021

PerkinElmer, Inc. Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations

PerkinElmer, Inc. Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening

PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process

Perkinelmer Launches First Cell Painting Kit